SPY425.26+0.95 0.22%
DIA344.30-0.82 -0.24%
IXIC14,174.14+104.72 0.74%

BRIEF-Incyte And Morphosys Announce First Patient Dosed In Phase 3 Study

05/11/2021 16:54
BRIEF-Incyte And Morphosys Announce First Patient Dosed In Phase 3 Study

- Incyte Corp INCY.O:

  • INCYTE AND MORPHOSYS ANNOUNCE FIRST PATIENT DOSED IN PHASE 3 FRONTMIND STUDY EVALUATING TAFASITAMAB COMBINATION AS A FIRST-LINE TREATMENT FOR DIFFUSE LARGE B-CELL LYMPHOMA

Source text for Eikon: ID:nBw1YWGnfa

Further company coverage: INCY.O


(([email protected];))